Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Innovent Biologics ( (HK:1801) ) has shared an announcement.
Innovent Biologics said China’s National Medical Products Administration has approved the combination of its PD-1 inhibitor TYVYT (sintilimab injection) with ELUNATE (fruquintinib) for patients with locally advanced or metastatic renal cell carcinoma who have failed prior VEGFR-TKI therapy and are PD-1/PD-L1 treatment-naïve in the first-line setting. The green light, based on the Phase III FRUSICA-2 study showing a substantial progression-free survival benefit over axitinib or everolimus monotherapy, marks the tenth approved indication for TYVYT, strengthens Innovent’s position in immuno-oncology, and broadens treatment options for Chinese patients with advanced kidney cancer.
The FRUSICA-2 trial demonstrated that sintilimab plus fruquintinib more than tripled median progression-free survival versus standard second-line therapies and delivered higher response rates with a safety profile consistent with each agent’s known characteristics. The new indication further validates the sintilimab–fruquintinib regimen, now cleared for two hard-to-treat cancers, reinforcing Innovent’s strategy of combination regimens and potentially supporting wider clinical and commercial uptake in China’s oncology market.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$113.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
More about Innovent Biologics
Innovent Biologics is a China-based biopharmaceutical company focused on developing and commercializing innovative oncology therapies, including immuno-oncology drugs such as the PD-1 antibody sintilimab marketed as TYVYT. The group collaborates with multinational partners like Eli Lilly to advance targeted and combination treatments for difficult-to-treat cancers in its domestic market and beyond.
Average Trading Volume: 12,170,790
Technical Sentiment Signal: Buy
Current Market Cap: HK$138B
Find detailed analytics on 1801 stock on TipRanks’ Stock Analysis page.